Israel develops new instrument to detect liver disease in just 20 minutes

new methods have been found in the detection ofof liverdiseasesRecently, an Israeli high-tech company developed a rapid detection of liverdiseaseinstrument, it is not only convenient and practical, but also high accuracy, can completely replace the living tissue biopsy, for patients to relieve the liver examination and other great painAt present, there are two main detection methods fordisease
s in the liver: one is blood testtors to detect transaminase, anti-antiand and glycerin trilipids, etcThe accuracy of the first test method is poor, can not be completely based on it to determine whether the tested person has liver disease, so after obtaining abnormal blood test data, in order to further determine whether the patient is infected with various types of hepatitis, must do a second testThe method of biopsy of the patient's liver is not only expensive and long," but also tends to cause damage to the patient's liver, causing pain and danger to the patient (the mortality rate is one in ten thousand)The Israeli company's new medicalinstrument, called BreathID,, is a good solution to these problemsIn order to understand the magic effect of this newinstrument , the reporter recently came to the of hadassah Hospital, israeli medical treatment center in Israel using this instrument Medical experts and authorities briefed reporters on the working principle and use of the new instrument Sykes, head of marketing at the company that owns BreathID technology, says that carbon dioxide is about 5 percent of the gas that people exhale, and about 1 percent of these gases are made up of carbon 13 The technical principle of BreathID is based on the "molecular association energy" of continuous respiratory sampling technology, which analyzes and determines the status of liver function by detecting the ratio of carbon 13 to carbon 12 per million units of carbon dioxide gas exhaled by humans The specific method of use is to have the tester drink a drug containing carbon 13 (McSalciedin) to produce a metabolic reaction in the liver, re-use The BreathID technology to map the metabolic image of his liver, and compare it with the image data obtained through the liver biopsy to determine whether the liver function is abnormal Serkes said the new instrument has more than 60 patented technology, the technical thinking began from the study of exhalation to diagnose stomach disease originally evolved Due to difficulties such as investment and clinical trials in the research and development process, the technical research was not proceeding at that time, and after the study was turned to the field of diagnosis of liver function, the research progressed rapidly due to the involvement of hadassah hospital In 2006, BreathID company from the listed company Oridion, specializing in the promotion and application of BreathID technology, at present, Hadassah Hospital has used new equipment for 400 hepatitis B and C liver disease patients, as well as 100 non-alcoholic fatty liver disease patients conducted clinical trials, the data obtained by the trial and bio-tissue obtained by the results of 90% of the slicing rate In the treatment room of Hadassah Hospital, reporters saw that the patient sitting in the chair was wearing a nasal casing connected to the new instrument, and 20 minutes later, several images of liver function that could be diagnosed by the doctor were drawn by the instrument Professor Yalong Yilan, director of internal medicine at Hadassah Medical Center and president of the Israel Hepatology Research Association, said that for the diagnosis of liver function and liver diseases (especially hepatitis B and A), the BreathID instrument is a very effective testing equipment, which is convenient, fast, low cost and other advantages under the premise of ensuring accuracy, so the application prospects are very broad He said had already used the device as a test for patients' liver function, and several other major Israeli hospitals had begun using it According to reports, the current Asia-Pacific region hepatitis B patients accounted for about 10% of the total population, hepatitis C is 2.5% From the point of view of diagnosis of liver function, BreathID technology can continuously and real-time determine liver function, liver fibrosis level and liver inflammation, distinguish between fatty liver disease, the test results can be highly consistent with the live tissue slicing Professor Yilan told reporters that it is precisely because of the high accuracy and reliability of The BreathID device in diagnosing liver function, so as a doctor, there is no reason to refuse to use this convenient and fast and can relieve the pain of patients advanced medical equipment (reprinted from Science and Technology Daily)